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Covalent protein adducts formed after exposure to xenobiotics may provide readily measurable
indicators of these exposures. After adequate characterization of the dose-dependent formation
of a specific adduct, the adduct can often be used as a quantitative marker for exposure, DNA
adduct formation, or, possibly, risk of disease. By elucidating the structure of an adduct and
studying the conditions under which it forms, information about the reactions that lead to its
formation can be obtained. Continuing work in this area includes methods to expand the number,
types, and levels of chemical exposures that can be studied by covalent adduct formation. In
addition to the use of this technology in the field of occupational health, basic research in this area
provides insights into metabolic pathways and biochemistry, as well. Environ Health Perspect
104(Suppl 5):879-882 (1996)
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Introduction
A number ofhuman diseases may result, at
least in part, from exposure to chemicals. A
dose-response relationship between disease
and chemical exposure, however, can be
difficult to establish. Although the occur-
rence ofdisease can be recorded, humans
are typically exposed to low levels ofchem-
icals present in complex mixtures over
extended periods. Lacking objective mea-
sures of exposure, epidemiologists have
been required to estimate exposure to
chemicals using surrogate measures such as
questionnaire data on lifestyle factors, past
occupations, or medication.
Considerable research has been devoted
to developing biomarkers that function as
measures ofdose, including urinary metabo-
lites or blood levels ofparent compounds
or their metabolites. Recent innovations
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allow the detection ofcovalent interactions
of xenobiotics with proteins and other
macromolecules, providing a method to
accurately measure exposure or acting as a
surrogate marker for dose at the target tis-
sue. Blood, for example, contains large
amounts of hemoglobin (Hb) and serum
albumin, which have reactive carboxyl,
amino, and sulfhydryl groups that can
interact with electrophilic compounds.
Adducts formed with these proteins are
often relatively long lived in the body
(compared to the biological half-life ofthe
exposure compound or its unbound
metabolites). The lifespan ofHb in human
red blood cells, for example, is approxi-
mately 4 months, allowing assessment of
cumulative doses from exposures during
this time. Because many of the reactive
metabolites of organic compounds that
form protein adducts also bind DNA,
some protein adducts can serve as markers
ofDNA binding or damage as well.
In this review we discuss recently
reported uses of Hb and serum albumin
adducts for determining exposure, for esti-
mating genetic damage and disease risk,
and studying reactions and metabolic path-
ways. Some analytical methods that have
been used in these studies are also included.
Estimation of Exposure,
DNA Adduct Levels, and Risk
of Disease
Traditionally, blood protein adduct analysis
has been used to assess and estimate
the dose associated with exposures to xeno-
biotics. The potential effects of these
exposures have also been studied using
adducts. Several recently reported examples
ofthese applications are discussed below.
Occupational exposure measurements
continue to be the focus of much of the
latest protein adduct work. Autrup et al.
(1), for example, measured the exposure of
animal feed production workers to the liver
carcinogen aflatoxin B1 (AFB1) using serum
albumin adducts. This group demonstrated
the formation ofAFB1 adducts with a
detection limit of 5 pg/mg serum albumin
using an enzyme-linked immunosorbent
assay (ELISA). Other researchers have mea-
sured the exposure ofworkers to 2,4-diflu-
oroaniline (2) and to ethylene oxide using
Hb adducts (3). Goergens et al. (4) moni-
tored fumigators for exposure to methyl
bromide using methylated cysteine from
Hb and serum albumin. This study detected
exposure in workers despite their use of
respiratory protection during fumigation
operations.
Exposure to several dietary carcinogens
has also been the subject of studies and
monitoring method development. Many
recent studies have focused on heterocyclic
amines, some ofwhich form adducts that
may serve as acceptable biomarkers. In an
assessment ofhuman exposure to 3-amino-
1,4-dimethyl-5H-pyrido[4,3-b]indole,
Umemoto et al. (5) detected Hb adducts
formed from this material in human blood
samples. Other researchers, however, have
reported analytical methods for measure-
ment of heterocyclic amine adducts that
appear to be unsuitable for exposure assess-
ment. Lynch et al. (6) examined the use of
the serum albumin adducts of the food-
borne heterocyclic amine 2-amino-3,8-
dimethylimidazo[4,5-f] quinoxaline and
were unable to detect this adduct in the
blood of human volunteers. They attrib-
uted this to low levels of formation of the
compound as well as to limited recovery in
the analytical process.
The measurement of protein adducts
can be quantitative ifdose-dependent for-
mation has been demonstrated, as is the
case for a variety ofadduct-forming com-
pounds, including 4,4'-methylenedianiline
(7) in rats and 7H-dibenz[c,g]carbazole in
mice (8). In humans, Vineis et al. (9) has
shown that 4-aminobiphenyl-hemoglobin
(4ABP-Hb) adduct levels in smokers reflect
the number ofcigarettes smoked. Walker et
al. (10), however, found that high levels of
ethylene oxide exposure caused distur-
bances in erythropoeisis and erythrocyte
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lifespan in rodents. This limits the ability
to relate exposure to Hb adduct levels at
high concentrations ofthis material.
The use ofblood protein adduct levels
as indicators of DNA adduct levels has
been reported since the 1970s (11,12) and
continues to be an active area of research.
Recent work has sought to establish quan-
titative relationships between protein
adduct levels and DNA adduct or damage
levels. Umemoto et al. (5) demonstrated a
correlation between Hb and liver DNA
adducts of 3-amino-1,4-dimethyl-5H-
pyrido[4,3-b]indole in rats and suggested
the use of this adduct for monitoring in
humans (Figure 1). The relationships
between protein and DNA adducts of7H-
dibenzo[c,g]carbazole in mice were studied
by Meier and Warshawsky (8). Liver
DNA, compared to other tissues studied,
preferentially binds this compound and
was shown to form adducts in a manner
that was proportional to dibenzo[c;g]car-
bazole-Hb adduct formation. Anwar et al.
(13) demonstrated a relationship between
levels of serum albumin-AFBI adduct
levels and indicators ofcytogenetic damage
(micronuclei per 500 polychromatic
erythrocytes per animal and chromosomal
aberrations per 50 metaphases per animal)
in bone marrow cells of rats treated with
this compound. In this study, protein
adducts appeared to provide a much more
sensitive marker of exposure than did
cytogenetic changes.
Efforts have also been made to corre-
late protein adduct levels and risk of
disease, assuming the existence of the
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Figure 1. Correlation between hemoglobin and liver
DNA adducts in rats exposed to 3-amino-1,4-dimethyl-
5H-pyrido[4,3-bMindole. From Umemoto et al. (5).
adduct provides an indication of this risk.
In a comparison across three ethnic groups,
Yu et al. (14) demonstrated a correlation
between acetylator phenotype, which could
be determined by ABP-Hb adduct levels,
and bladder cancer incidence. In a study of
Hb adducts ofacrylamide in exposed work-
ers at a chemical factory and the signs and
symptoms of the peripheral neuropathy
that can result from exposure to this mater-
ial, Calleman et al. (15) found a correlation
between exposure and disease. In contrast, a
comparison of lung cancer patients and
controls by Weston et al. (16) demon-
strated that 4ABP-Hb adduct levels do not
correspond tolung cancer incidence.
Studies of Metabolism
In addition to their use as markers ofexpo-
sure, surrogate markers for DNA adduct
formation, and indicators ofpotential dis-
ease risk, certain protein adducts may pro-
vide information about metabolism. The
presence ofan adduct may suggest the for-
mation ofa reactive intermediate. Bryant
et al. (17), for example, demonstrated the
formation of the N-hydroxy derivative of
2,6-dimethylaniline by measuring the Hb
adduct ofthis compound from lidocaine-
treated patients. This derivative may indicate
the presence of the reactive intermediate
responsible for the reported mutagenicity
of2,6-dimethylaniline in animals, a major
metabolite ofthis anesthetic. Zwirner-Baier
and Neumann (18) used the Hb adducts of
Direct Red 46 and Pigment Yellow 17 to
study the metabolic fate of azo dyes in
Wistar rats. Because ofthe insolubility and
low bioavailability ofPigment Yellow 17, it
was thought that this material posed little
risk as a carcinogen. Although found at low
levels after chronic administration, hydro-
lyzable Hb adducts, which suggest the
generation of reactive intermediates, were
formed from both ofthese compounds.
Protein adduct measurement methods
have been used to study specific reactions,
as well. The P4501A2-catalyzed reaction
responsible for the metabolically activating
N-oxidation of 4ABP has been assessed
using Hb adducts, which arise from the N-
hydroxy form ofthis compound. In astudy
by Hammons et al. (19), the P4501A2
inhibitor 2-ethylnaphthalene caused a dose-
dependent decrease in 4ABP-Hb adducts
in rats. Methimidazole, an inhibitor of
flavin monooxygenase, did not affect
adduct levels. Vineis et al. (9) used levels
of4ABP-Hb adducts to identify geneti-
cally determined slow acetylators, which
had higher levels of this adduct. This
reflected the decreased levels ofdetoxifying
N-acetylation in these individuals.
The structure ofblood protein adducts
may also provide structural information
about the reactive species responsible for
adduct formation. Day et al. (20) studied
the chiral specificity of serum albumin-
benzo[a]pyrene (B[a]P) adduct formation.
B[a]P anti-diol epoxide (B[a]PDE) forms
adducts through either carboxylic acid
esters or through a histidine (imidazole)
nitrogen in human serum albumin in vitro
(20,21). This study demonstrated the
binding ofthe less toxic (-) enantiomer to
histidine(146) and the more carcinogenic
and mutagenic (+) enantiomer to carboxyl
groups ofaspartate(187) or glutamate(188)
on human serum albumin (20). Another
study by Day et al. (22) confirmed the spe-
cific histidine nitrogen on human serum
albumin through which these adducts form,
as well as the B[a]PDE carbon involved.
Analytical Methods
Several analytical methods have been used
for the detection and quantitation ofcova-
lent blood protein adducts. Adducts often
must be adequately identified and charac-
terized before their use in monitoring or in
the course of studies of metabolism.
Protein adducts may be analyzed intact, as
peptide fragments, as modified amino
acids, or as released parent compounds.
The following examples ofmethods used
to detect and measure adducts ofAFB1,
polycyclic aromatic hydrocarbons (PAHs),
and aromatic amines illustrate responses to
differing requirements.
Analytical methods that are time and
labor saving have often been used in
studies that involve testing large numbers
ofindividuals. Accordingly, immunoassays
have been commonly used to measure
AFBI-serum albumin adducts in screening
programs (23). Wild et al. (24) compared
three methods for measuring these adducts.
Enzymatic hydrolysis of serum albumin
followed by ELISA was found to be better
suited for large-scale screening than direct
ELISA and high performance liquid
chromatography (HPLC). They also found
that HPLC/fluorescence resulted in fewer
false positives and was useful if time and
conditions allowed.
Many recently reported methods for
the analysis of PAH adducts have been
designed to study or characterize structure.
This goal has been reflected in the analy-
tical methods, which have often used
relatively sophisticated analyses. Initial pro-
teolytic cleavage ofadducted proteins can
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release adducts sequestered within hydro-
phobic regions of the protein or expose
them to aqueous environments in which
hydrolysis can take place. Shugart (25)
used acid hydrolysis of B[a]P adducts to
generate free tetrols, followed by HPLC/
fluorescence. Day et al. (20-22) used a
series of physicochemical methods to
establish the amino acid and enantio-speci-
ficity of B[a]PDE binding. Included
among these were fluorescence line narrow-
ing spectroscopy and HPLC/fast atom
bombardment mass spectrometry (MS).
Some aromatic amine adducts may be
analyzed using similar methods. In recently
reported studies of aromatic amine-Hb
adducts, the adducting compound was
removed before quantitation. Some aro-
matic amines form cysteine adducts with
Hb that can be released with mild base or
acid hydrolysis. Cheever et al. (26) used
HPLC with a fluorescence detector to mea-
sure o-toluidine adducts isolated from both
Hb and serum albumin in rats using base
hydrolysis. Zwirner-Baier and Newmann
(18) used alkaline conditions to isolate
adducts followed by quantitation by
HPLC with an electrochemical detector to
study the bioavailabilty of the azo dye
Pigment Yellow 17. Base hydrolysis was
used in conjunction with GC-MS by
Bailey et al. (7) to analyze rat Hb for 4,4-
methylenedianiline and with GC/negative
ion chemical ionization-MS in studies by
Weston et al. (16) and Vineis et al. (9) to
study 4ABP-Hb adducts in humans.
Conclusions
Work continues on the development of
methods that allow for practical applica-
tions ofprotein adduct measurement, such
as those designed to assess exposure to
chemicals as well as the effects of these
exposures. The ability to measure blood
protein adducts also provides a method of
studying complex metabolic processes. In
addition to advancing technology associ-
ated with a variety of analytical methods,
these studies generate valuable information
about the exposure to and metabolism of
xenobiotics. Only a sampling of recent
protein adduct work has been discussed;
numerous studies have been carried out to
identify and quantify protein adducts,
to improve analytical techniques, and to
apply these improvements to new settings
and chemicals.
The information obtained in these
studies must, however, be interpreted care-
fully. As the measurement becomes farther
removed from the event for which it serves
as a surrogate, an understanding of the
biological mechanisms responsible for the
adduct formation becomes increasingly
important. The qualities that make blood
protein adducts useful as biomarkers, such
as access and stability, also demonstrate the
differences between the measured adducts
and the events for which they serve as
markers. Target tissue DNA, for example,
may be somewhat less accessible by a
chemical and is subject to repair mecha-
nisms. A linear relationship between levels
of DNA adducts and those formed with
blood proteins may not exist. Assigning
value to blood protein adducts for this
purpose may be a highly empirical process.
Relationships between disease risk and
blood protein adduct levels may be even
more difficult to establish. In addition to
factors such as distribution and DNA
repair, the development of disease, espe-
cially cancer, is not a simple process.
According to the multistage model ofcar-
cinogenesis, for example, several events
must take place for the development ofdis-
ease. As a marker of DNA adduct forma-
tion that may lead to mutation events, a
protein adduct may only serve to provide a
marker for one part ofa complex process.
Cautious interpretation of these data is
often required.
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